Advertisement

General

  • Hisham Fansa
  • Christoph Heitmann
Chapter

Abstract

According to the German Robert Koch Institute, breast cancer is the most frequent malignant disease in women. They predict 72,000 newly diagnosed patients in 2018. In 2015 mortality was almost 18,000. One of eight women will get breast cancer during her lifetime; 3 out of 10 are younger than 55 when diagnosed. The relative (cancer-related) 5-year survival rate in 2013/2014 was 88%; the 10-year survival rate was 82%. The data is comparable for most developed nations. Although the treatment of breast cancer is very similar in all developed nations, in this chapter we describe the way according to the German guidelines.

Literature

German Guidelines on Diagnosis, Therapy and After Care (in German)

  1. 2.
  2. 3.
    Cochrane:Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;11:CD002748.Google Scholar
  3. 4.
    Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887–92.CrossRefGoogle Scholar
  4. 5.
    Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, SA ML, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Hisham Fansa
    • 1
    • 2
    • 3
  • Christoph Heitmann
    • 4
  1. 1.Department of Plastic, Reconstructive and Aesthetic SurgeryKlinikum BielefeldGermany
  2. 2.Center for Aesthetic Plastic Surgery and Reconstructive Breast SurgeryMunichGermany
  3. 3.Center for Aesthetic Plastic Surgery and Reconstructive Breast SurgeryZurichSwitzerland
  4. 4.Practice for Plastic SurgeryMunichGermany

Personalised recommendations